General Workings Inc.

San Francisco, CA · Founded 2011 · CIK 0001639729 · Biotech

Oral GLP-1 peptide therapeutics and portable bioreactor platform for peptide manufacturing

general.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$12M
1 Form D · Apr 2015
138 months since last filing
Contracts
—
No federal contracts on record
Patents
3
1 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$12,340,982
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2032Atea Pharmaceuticals—$156M
2033Orthogonal Biologics, Inc.——
2034CALIFIA BIO, INC.——
2035General Workings Inc.—$12M
2036Endomet Biosciences, Inc.——
2037Apeximmune Therapeutics Inc.——
2038VXBIOSCIENCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Murtaza HussainDirector · Executive Officer
  • Ali MoizDirector

Patents

USPTO · 1 granted of 3

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.